The U.S. Food and Drug Administration has approved Impel NeuroPharma’s Trudhesa to treat migraine headaches, the Seattle company announced Friday. Trudhesa leverages Impel’s upper nasal spray system to deliver a… Read More
Seattle-based biotech firm Impel NeuroPharma closed its latest round of funding, bringing in $67.5 million to develop treatments for central nervous system disorders, such as migraines and Parkinson’s. This is… Read More